Related Experiment Video

Updated: May 23, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

The role of the PI3K-AKT pathway in melanoma

Michael A Davies1

  • 1Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. mdavies@mdanderson.org

Cancer Journal (Sudbury, Mass.)
|March 29, 2012
PubMed

Insights

The phosphatidylinositol 3-kinase (PI3K)-AKT pathway is crucial in melanoma development and resistance to therapy. Understanding its complex regulation is key to developing effective PI3K-AKT inhibitors for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • The phosphatidylinositol 3-kinase (PI3K)-AKT pathway is a critical signaling network implicated in various cancers.
  • Aberrant activation of the PI3K-AKT pathway is frequently observed in melanoma, often co-occurring with RAS-RAF-MEK-ERK pathway activation.

Purpose of the Study:

  • To review the evidence supporting the role of the PI3K-AKT pathway in melanoma initiation and therapeutic resistance.
  • To highlight the significance of understanding PI3K-AKT pathway complexity for rational drug development.

Main Methods:

  • Review of genetic and epigenetic alterations activating the PI3K-AKT pathway in melanoma.
  • Analysis of functional experiments demonstrating the pathway's role in melanoma.
  • Assessment of the therapeutic landscape of PI3K-AKT inhibitors.

Main Results:

  • Genetic and epigenetic events contribute to PI3K-AKT pathway activation in melanoma.
  • The PI3K-AKT pathway is vital for both melanoma initiation and the development of resistance to treatments.
  • Numerous PI3K-AKT pathway inhibitors are progressing towards clinical trials.

Conclusions:

  • The PI3K-AKT pathway is a significant driver in melanoma pathogenesis and treatment resistance.
  • Further elucidation of PI3K-AKT pathway regulation is essential for optimizing targeted therapeutic strategies.
  • Clinical trials investigating PI3K-AKT inhibitors hold promise for melanoma treatment.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...